Menu Search
Equities

Establishment Labs Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3E0:FRA

Establishment Labs Holdings Inc

Actions
  • Price (EUR)61.00
  • Today's Change0.50 / 0.83%
  • Shares traded62.00
  • 1 Year change+122.63%
  • Beta0.9233
Data delayed at least 15 minutes, as of Feb 13 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.

  • Revenue in USD (TTM)190.97m
  • Net income in USD-82.98m
  • Incorporated2013
  • Employees1.02k
  • Location
    Establishment Labs Holdings IncBuilding B15 And 25 Coyol Free ZoneALAJUELA 20101Costa RicaCRI
  • Phone+506 24342400
  • Websitehttps://establishmentlabs.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.